ONCE-MONTHLY EFIMOSFERMIN ALFA IMPROVES NON-INVASIVE MARKERS OF FIBROSIS WITH AN ACCEPTABLE SAFETY PROFILE IN PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS WITH MODERATE TO ADVANCED FIBROSIS OR COMPENSATED CIRRHOSIS (F2–4): RESULTS UP TO 52 WEEKS FROM AN OPEN-LABEL, PHASE 2 STUDY (AASLD 2026) - Oct 6, 2026 - Abstract #2299; Pres time: Nov 6, 2026; 01:00 PM - 02:00 PM; Location: Convention Center: Poster Hall, Hall DE; P2 | "Efimosfermin 225 mg and 300 mg demonstrated similar improvements in non-invasive markers of fibrosis and an acceptable, well-tolerated safety profile with comparable pharmacokinetics through 52 weeks in pts with F2–4 MASH. These results support continued evaluation of pts with advanced fibrosis and compensated cirrhosis in Phase 3 trials."
Clinical • Metastases • Non-invasive • P2 data • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • FGF21
|
|
Mazen Noureddin1; Rohit Loomba2; Janelle Lennie3; Margaret James Koziel4; Brenda Jeglinski4; Matthew Bryant4; Patricia Mendez3; Stuart Kendrick5; Anthony Lones5; Victoria Woodham6; Edoardo Lisi5; Sumanta Mukherjee3; Eric Lawitz7
|